India Mucormycosis Treatment (Black Fungus Drugs) Market Analysis & Forecast: 2026-2033

India Mucormycosis Treatment (Black Fungus Drugs) Market Size and Forecast – 2026 to 2033

The India Mucormycosis Treatment (Black Fungus Drugs) Market is anticipated to grow at a CAGR of 7.3% with USD 9.4 Mn share in 2026 and is expected to reach USD 12.2 Mn in 2033. The rising prevalence of diabetes, increasing number of immunocompromised patients, and growing awareness of early diagnosis drive the India mucormycosis treatment (black fungus drugs) market. Approximately 589 Mn adults aged 20–79 years are living with diabetes, with this number projected to reach 853 Mn by 2050.

Key Takeaways

• Rhizopus hold the largest market share of 38.7% in 2026 owing to its rising prevalence of diabetes. India is facing a major diabetes epidemic, with over 101 Mn diagnosed cases and 136 Mn people with pre-diabetes.
• Magnetic Resonance Imaging (MRI) expected to hold largest market share of 42.2% in 2026 owing to the improved diagnostic accuracy.
• Amphotericin B acquired the largest market share of 37.7% in 2026 owing to its first-line standard of care.
• Hospital Pharmacies captures the largest market share of 42.8% in 2026 owing to the hospital-based management of mucormycosis.

Current Events and Their Impact on the India Mucormycosis Treatment (Black Fungus Drugs) Market 

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Magnetic Resonance Imaging (MRI) expected to hold largest market share

Magnetic Resonance Imaging (MRI) expected to hold largest market share of 42.2% in 2026 owing to the expansion of advanced imaging infrastructure. Healthcare providers drive the India mucormycosis treatment (black fungus drugs) market by using Magnetic Resonance Imaging (MRI) to detect fungal invasion in the sinuses, orbit, and brain at an early stage. Clinicians use MRI to evaluate disease severity, plan surgical interventions, and monitor treatment response, enabling prompt initiation of antifungal therapy. Hospitals continue to expand advanced MRI facilities while adopting standardized diagnostic protocols and strengthening clinical awareness. These efforts accelerate diagnosis, improve patient management, and increase the demand for effective mucormycosis treatments across India. In March 2026, Prenuvo, a Redwood City-based startup launched an annual imaging subscription service to encourage repeat use. The company announced Monday that its Core Membership will cost $1,199 per year. Prenuvo already offers elective whole-body MRI scans for $2,499 to healthy individuals seeking early detection of potential health issues before symptoms appear.

Why is Rhizopus Acquiring the Largest Market Share?

Rhizopus hold the largest market share of 38.7% in 2026. Rhizopus drives the India mucormycosis (black fungus) treatment market as the leading fungal genus responsible for most reported infections. India's large population of patients with uncontrolled diabetes, along with the growing number of immunocompromised individuals, cancer patients, and transplant recipients, increases the incidence of Rhizopus-related infections. Rhizopus species account for over 90% of global mucormycosis cases. Healthcare providers are improving clinical awareness, adopting advanced laboratory testing and imaging for earlier diagnosis, and expanding access to antifungal therapies, all of which boost treatment demand. At the same time, expanding tertiary healthcare facilities and stronger hospital preparedness continue to enhance effective mucormycosis management across the country.

Amphotericin B acquired the largest market share

Amphotericin B acquired the largest market share of 37.7% in 2026. Healthcare providers drive the India mucormycosis treatment (black fungus drugs) market by using Amphotericin B as the primary first-line therapy for severe and life-threatening fungal infections. Clinicians actively administer liposomal and conventional formulations to treat patients with diabetes and weakened immunity. Hospitals increasingly prioritize rapid antifungal intervention, strengthen preparedness following COVID-19-associated mucormycosis cases, and improve access through expanded domestic production. Growing tertiary care infrastructure and enhanced diagnostic capabilities help clinicians initiate treatment earlier, further increasing demand for Amphotericin B across India. For instance, Celon Laboratories has launched an alternative drug, Amphotericin B Emulsion, to treat mucormycosis (black fungus). Amphotericin B plays a key role in treating the infection, which has recently surged among COVID-19 patients across India.

Which Distribution Channel segment dominates the market? 

To learn more about this report, Request Free Sample

Hospital Pharmacies captures the largest market share of 42.8% in 2026. Key drivers of the hospital pharmacies mucormycosis treatment (black fungus drugs) market in India include rising mucormycosis increasing diabetes prevalence, and a growing immunocompromised population due to cancer treatments and organ transplants. Cancer is a major public health concern in India, where about 1 in 9 individuals is projected to develop the disease in their lifetime, with over 15.6 lakh new cases and around 8.7 lakh deaths annually. High steroid use during COVID-19 management and greater clinical awareness also increase demand for antifungal drugs such as amphotericin B, posaconazole, and isavuconazole in hospital pharmacies. Strong procurement systems, government treatment guidelines, and expanded supply chains ensure consistent availability of essential medicines.

India Mucormycosis Treatment (Black Fungus Drugs) Market Trends

• India has over 101 million people living with diabetes, making it one of the largest diabetic populations globally. Diabetes is a key risk factor for mucormycosis due to immune suppression and ketoacidosis risk.
• During the mucormycosis surge in 2021, the Government of India allocated over 29 lakh vials of Amphotericin B to states/UTs to manage emergency demand and shortages.
  This reflects the scale of sudden national-level drug requirement for mucormycosis management.
• The Directorate General of Health Services (DGHS) issued national guidelines recommending Liposomal Amphotericin B as first-line therapy, followed by azoles such as posaconazole and isavuconazole for step-down treatment.
  This standardization increased uniform procurement across government and private hospitals.

Who are the Major Companies in India Mucormycosis Treatment (Black Fungus Drugs) Industry

Some of the major key players in India Mucormycosis Treatment (Black Fungus Drugs) are Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs

Key News

• In March 2021, Strides Pharma Science has partnered with Taiwan-based TLC to introduce Liposomal Amphotericin B in India for treating mucormycosis (black fungus).

Market Report Scope

Analyst Opinion

• India’s mucormycosis treatment (black fungus drugs) market is fundamentally demand-driven rather than trend-driven, as clinical burden—not optional care—dictates therapy usage. During the COVID-19 surge, India reported over 47,000 mucormycosis cases, accounting for the majority of global cases, clearly showing how sharply the disease can escalate under immunological stress conditions.
• The market is structurally linked to diabetes prevalence, with India housing over 100 million diabetic patients, a major at-risk group for mucormycosis due to impaired immunity and hyperglycemia-driven fungal growth. This creates a persistent, non-cyclical demand base for antifungal agents like amphotericin B and posaconazole in hospital settings.
• Hospital dependency is exceptionally high, as mucormycosis is an acute, life-threatening condition with reported mortality rates ranging between 40% and 80% depending on organ involvement and treatment delay. This forces immediate adoption of high-cost, high-intensity antifungal regimens without substitution flexibility, reinforcing strong hospital pharmacy consumption.
• Clinical response patterns further reinforce market rigidity—liposomal amphotericin B remains the gold standard despite supply constraints, evidenced during 2021 when India faced severe shortages amid peak infections, pushing hospitals to ration doses and prioritize critical cases.
• Overall, the market is shaped less by innovation cycles and more by epidemiological pressure, late-stage diagnosis patterns, and urgent inpatient treatment requirements, making it one of the most necessity-driven segments within infectious disease therapeutics in India.

Market Segmentation

• By Species (Revenue, USD Mn, 2021-2033)
  • Rhizopus
  • Cunninghamella
  • Rhizomucor
  • Saksenaea
  • Apophysomyces
  • Lichtheimia
  • Mucor
  • Others
• By Diagnosis Method (Revenue, USD Mn, 2021-2033)
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Tissue Biopsy
  • Others
• By Drugs (Revenue, USD Mn, 2021-2033)
  • Amphotericin B
  • Isavuconazole
  • Posaconazole
  • Voriconazole
  • Flucytosine
  • Fluconazole
  • Others
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Sources

Primary Research interviews

• Interviews with infectious disease specialists and mycology experts in major hospitals across India
• Discussions with pharmacists and critical care physicians involved in antifungal drug administration
• Inputs from hospital procurement and formulary management teams
• Consultations with clinicians treating post-COVID mucormycosis cases

Databases

• PubMed and NCBI biomedical literature databases
• WHO Global Health Observatory data repository
• Indian Council of Medical Research (ICMR) datasets and publications
• Ministry of Health and Family Welfare (India) health statistics portal
• ClinicalTrials.gov for antifungal drug trials and studies

Magazines

• Medical and healthcare-focused publications covering infectious diseases
• Pharmaceutical industry magazines covering antifungal drug developments
• Public health and epidemiology magazines reporting fungal infection trends

Journals

• Journal of Medical Mycology
• Clinical Infectious Diseases journal
• Mycoses journal (medical fungal research)
• The Lancet Infectious Diseases
• Indian Journal of Medical Research

Newspapers

• National and regional Indian newspapers reporting on mucormycosis outbreaks
• Global newspapers covering post-COVID secondary infections and treatment updates
• Health and science sections of leading daily publications

Associations

• Indian Medical Association (IMA)
• Infectious Diseases Society of America (IDSA)
• European Confederation of Medical Mycology (ECMM)
• World Health Organization (WHO) fungal infection working groups
• Indian Society of Medical Microbiologists

Public Domain sources

• Government health bulletins and advisories on mucormycosis
• WHO fact sheets and epidemiological reports
• Open-access medical research articles
• Hospital and university published case studies
• Regulatory authority drug safety communications

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years